1 story in the last 7 days
The latest alembic pharma news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks alembic pharma across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Alembic Pharmaceuticals received tentative USFDA approval for its generic Binimetinib tablets in 45mg strength. The drug is used in combination therapies for melanoma and lung cancer. Alembic previously received tentative approval for the 15mg strength and may qualify for marketing exclusivity.
Summaries by ByteBrief